GC Pharma, a South Korean biopharma formerly known as Green Cross Corporation, has set up a USA-based company dedicated to the development of new vaccines.
The new company, called Curevo, has been formed based on a strategic collaboration between GC Pharma, the USA’s Infectious Disease Research Institute (IDRI) and Seoul-based Mogam Institute for Biomedical Research (MIBR).
"MIBR scientists have been focusing on discovering novel cancer therapeutics and vaccines. Curevo creates an excellent conduit to achieve those goals"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze